Spotlight: Implications of Just Published New PTAB Rules
The use of inter partes review (IPR) to challenge bio/pharma patents has grown significantly — with the number nearly doubling in 2015 alone. While relatively few of them have reached final decisions, what gives some challengers the winning edge?
Please join our experienced attorneys for a discussion on the key challenges you could face with your next IPR, as well as your overall strategies for patent litigation and enforcement, and how to prepare to address them.
Topics include:
- Determining trends based on the first 105+ bio/pharma IPR petitions to be filed
- Discovering the most vulnerable types of bio/pharma patents
- Learning how to prosecute bio/pharma patents to withstand IPR
- Employing tactics to help prevent an institution decision
- Understanding more about biosimilar and biologics-related IPRs
- Reviewing updates on PTAB rule changes
Speakers
Stephen Maebius, Partner, IP Department, Foley & Lardner LLP
Kristel Schorr, Partner and Chair, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
Moderator
Etsuo Doi, Managing Partner, Tokyo Office, Foley & Lardner LLP
People
Related Insights
26 July 2024
Video
Ten Minute Interview: Art Ownership
Brian Lucareli, director of Foley Private Client Services and co-chair of Foley’s Family Offices group, sits down with Lindsey Birch, associate and member of our Intellectual Property practice group, for a 10-minute interview to discuss art ownership.
26 July 2024
Foley In Fashion
Passing the Torch: Technology in the Opening Ceremony Fashion at the Paris Olympics
With the 2024 Olympic Games set in Paris, France, one of the world’s fashion capitals, athletics and aesthetics collide to take center stage at the much-anticipated opening ceremony.
25 July 2024
Foley In Fashion
SHEIN’s $1.9 Million Data Breach: A Cautionary Tale for Online Fashion Brands
The New York Attorney General fined fast-fashion company, Shein Distribution Corporation, $1.9 million for failing to properly handle a data breach in late 2022.